Busca avançada
Ano de início
Entree


Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial

Texto completo
Autor(es):
Mostrar menos -
Bulubas, Lucia ; Goerigk, Stephan ; Gomes, July S. ; Brem, Anna-Katharine ; Carvalho, Juliana B. ; Pinto, Bianca S. ; Elkis, Helio ; Gattaz, Wagner F. ; Padberg, Frank ; Brunoni, Andre R. ; Valiengo, Leandro
Número total de Autores: 11
Tipo de documento: Artigo Científico
Fonte: SCHIZOPHRENIA RESEARCH; v. 235, p. 8-pg., 2021-07-22.
Resumo

Cognitive deficits and negative symptoms in schizophrenia are associated with poor functional outcomes and limited in terms of treatment. The Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) trial has shown efficacy of transcranial direct current stimulation (tDCS) for improving negative symptoms. In this secondary analysis, we investigate its effects on cognitive performance. In STARTS, a double-blinded, sham controlled, randomized clinical trial, patients were treated with twice-daily, 20-min, 2-mA fronto-temporal tDCS over 5 days or sham-tDCS. In 90 patients, we evaluated the cognitive performance up to 12 weeks post-treatment. We found that active-tDCS showed no beneficial effects over sham-tDCS in any of the tests. Based on a 5-factor cognitive model, improvements of executive functions and delayed memory were observed in favor of shamtDCS. Overall, the applied active-tDCS protocol, primarily designed to improve negative symptoms, did not promote cognitive improvement. We discuss possible protocol modification potentially required to increase tDCS effects on cognition. ClinicalTrials.gov identifier: NCT02535676 (AU)

Processo FAPESP: 17/50223-7 - BAYLAT: Multimodal approaches in experimental psychology and clinical neuroscience and psychiatry: research groups from Bavaria and São Paulo | São Paulo - SP
Beneficiário:Andre Russowsky Brunoni
Modalidade de apoio: Auxílio Organização - Reunião Científica
Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
Beneficiário:Wagner Farid Gattaz
Modalidade de apoio: Auxílio à Pesquisa - Temático